Almost a year after two historic approvals, Pfizer is pulling a sickle cell disease treatment from the market, and the ...

SAN FRANCISCO, Oct. 31, 2024 /PRNewswire/ -- Pfizer, Inc. and Global Blood Therapeutics, Inc. were sued in San Francisco Superior Court where the plaintiff alleges the drug Oxbryta contributed to ...

Pfizer Inc (PFE) reports a 32% operational revenue growth and raises full-year guidance, despite challenges in COVID-19 ...

Pfizer is voluntarily withdrawing its sickle cell disease (SCD) therapy Oxbryta from all world markets after finding an "imbalance" in deaths in its clinical trials programme. It's a blow to the ...

Pfizer Inc. Chief Executive Officer Albert Bourla said he’ll do “whatever it takes” to keep profits growing, including ...

"Based on our investigation, we believe that Oxbryta carries unreasonable and unwarned risks to its users. We are proud of all of the SCD patients who have stepped forward to provide assistance in ...

It has been nearly two years since Pfizer’s sickle cell disease (SCD) therapy Oxbryta was approved in the UK, but patients will now be able to access the treatment after an agreement was reached ...

Pfizer in September recalled the sickle cell anemia treatment Oxbryta due to safety concerns. The drug was gained in the 2022 purchase of Global Blood Therapeutics Inc. for $5.4 billion.

Omni Family of Services, a national leader in child welfare and behavioral health, is excited to announce its expansion into Ohio, bringing critical behavioral health services to youth and families.

The Society for Immunotherapy of Cancer (SITC) received over 1,500 abstract submissions in 2024, and has announced titles and authors for 42 accepted Late-Breaking Abstracts (LBA). New for 2024, all ...